CTLA4 and neoplasm: Therefore, these novel anti-PD-L1 and anti-CTLA-4 mAbs could be useful, especially against tumors with reduced expression of MHC complex, where NK cells could serve as the main players in anti-tumor response, since T cells activity might be impaired.